Floatz Rating
BBB74/100
Confidence
Indicative
Sponsor
Shire
Modality
UNKNOWN
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00432510CT.gov Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects | — | Completed | — | — | — |
NCT00438815CT.gov Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks | — | Completed | — | — | — |
NCT00462709CT.gov Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks | — | Completed | — | — | — |
NCT00289211CT.gov C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks | — | Completed | — | — | — |
NCT01005888CT.gov C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hereditary Angioedema
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| c1 esterase inhibitor [human] (this asset) | Shire | P3 | BBB · 74 |
| Firazyr | Nang Kuang Pharmaceutical Co., Ltd. | P4 | A |
| Sebetralstat | KalVista Pharmaceuticals, Ltd. | P4 | A |
| Berotralstat | BioCryst Pharmaceuticals | P3 | A |
| Lanadelumab | Takeda | P3 | A |
| Garadacimab | CSL Behring | P4 | BBB |
| Deucrictibant | Institute for Asthma and Allergy | P3 | BBB |
| Ecallantide | NYU Langone Health | P3 | BBB |
| Conestat Alfa | CSL Behring | P3 | BBB |
+28 more in the Hereditary Angioedema cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. c1 esterase inhibitor [human] in Hereditary Angioedema. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/c1-esterase-inhibitor-human-hereditary-angioedema
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →